Overcoming Manufacturing Challenges For Accelerated Drug Development

There is a rise in the overall number of expedited development programs to address patients’ needs, requiring the pharmaceutical industry to adapt to new drug development life cycles. New drugs receiving expedited approval have shorter timelines, which can create unique challenges for development and manufacturing.

Drug development life cycles for these designations involve interwoven steps and related processes be executed within an accelerated timeline. The challenge is to leverage the drug development knowledge and build a strategy that maintains the integrity, quality, and timeliness of the manufacturing process.

Download the white paper and gain expert insights on overcoming manufacturing challenges associated with expedited development programs.